Free Newsletter
Novo plots Victoza launches in Germany, U.K.
Free newsletter via e-mail
Tools
Armed with European approval for its new diabetes treatment Victoza, Novo Nordisk plans a launch this summer in Britain, Germany and Denmark, with other European markets to follow. The company is still awaiting FDA's blessing after thyroid safety questions prompted questions from an expert advisory panel. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: